Tickers

1. Composite Trajectory Verdict

Given AVNT’s capital-intensive manufacturing model, significant debt obligations, and ongoing restructuring, all three financial statements carry roughly equal weight for assessing trajectory.

Composite Trajectory: Mixed

The annual income statement shows a sharp deterioration in 2025 (operating income -38%, net income -51%) driven by a $71.6 million ERP impairment, $48.4 million restructuring, and lower insurance recoveries, reversing the strong 2024 improvement. Quarterly earnings in 2026, however, show clear year-over-year improvement in both Q1 and Q2. Cash generation has improved steadily on an annual basis (operating cash flow rising from $201.6 million in 2023 to $301.6 million in 2025), though the first six months of 2026 dipped slightly versus 2025. The balance sheet has consistently strengthened, with total debt falling from $2,067 million at end-2024 to $1,923 million at end-2025 and further to $1,899 million at June 2026, while equity has grown.

2. Red Flags

• Large non-recurring charges in 2025: A $71.6 million impairment of the S/4HANA ERP system, $14.7 million for related hosting obligations, and $48.4 million total restructuring charges (vs. $4.5 million in 2024) drove the GAAP earnings collapse (10-K 2025, Note 3; 10-K 2025, Consolidated Statements of Operations).
• Environmental liability uncertainty: The Calvert City accrual stands at $133.2 million (total environmental accruals $141.2 million) with the company acknowledging that “additional costs in excess of the amount accrued… could be material” (10-K 2025, Note 10).
• IRS tax dispute: A Notice of Deficiency for the 2019 tax year proposes $23.8 million tax plus $7.3 million interest and a $4.8 million penalty; no provision has been recorded (10-K 2025, Note 11).
• GAAP earnings vs. cash flow divergence: 2025 net income of $83.6 million versus operating cash flow of $301.6 million, largely due to non-cash impairment and restructuring charges (10-K 2025, Consolidated Statements of Operations; 10-K 2025, Consolidated Statements of Cash Flows).
• Quarterly operating cash flow decline: Six-month 2026 operating cash flow of $59.3 million was $2.4 million below the same period in 2025, attributed to working capital investment and higher restructuring payments (10-Q Q2 2026, MD&A).

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Mixed

Annual GAAP earnings deteriorated markedly in 2025: sales rose only 0.6% to $3,260.2 million, gross margin fell 140 bps to 31.2%, operating income dropped 38% to $203.5 million, and net income attributable to Avient fell 51% to $81.9 million (10-K 2025, Consolidated Statements of Operations). The decline was explicitly attributed to the S/4HANA impairment ($71.6 million), higher restructuring ($48.4 million vs. $4.5 million), and lower insurance recoveries ($2.0 million vs. $34.7 million) (10-K 2025, MD&A). In contrast, quarterly 2026 results show year-over-year improvement: Q2 2026 operating income rose 17% to $112.4 million on 5.8% sales growth, and six-month operating income more than doubled to $208.2 million (though the 2025 comparator includes the Q1 2025 impairment) (10-Q Q2 2026, Condensed Statements of Operations). Q1 2026 operating income of $95.8 million compares to $0.7 million in Q1 2025 (10-Q Q1 2026, MD&A). The annual and quarterly series thus point in opposite directions.

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Improving

Annual operating cash flow has increased each year: $201.6 million (2023), $256.8 million (2024), $301.6 million (2025) (10-K 2025, Consolidated Statements of Cash Flows). Free cash flow (operating cash flow less capital expenditures) improved from $82.2 million (2023) to $134.9 million (2024) to $195.0 million (2025) (10-K 2025, Consolidated Statements of Cash Flows). Capital expenditures declined from $121.9 million (2024) to $106.6 million (2025). For the first six months of 2026, operating cash flow was $59.3 million, slightly below $61.7 million in the prior-year period, with the decrease attributed to working capital investment and higher restructuring payments (10-Q Q2 2026, Condensed Statements of Cash Flows; 10-Q Q2 2026, MD&A). The multi-year annual trend remains clearly positive.

5. Balance Sheet Assessment

Balance Sheet Trajectory: Improving

Total debt has declined steadily: $2,067.0 million at December 2024, $1,923.1 million at December 2025, and $1,898.6 million (principal maturities) at June 2026 (10-K 2025, Note 4; 10-Q Q2 2026, MD&A). The company made $150 million of voluntary term-loan prepayments in 2025 and a further $50 million in June 2026 (10-K 2025, Note 4; 10-Q Q2 2026, MD&A). Shareholders’ equity rose from $2,313.8 million to $2,374.2 million over 2025 and to $2,436.9 million at June 2026 (10-K 2025, Consolidated Balance Sheets; 10-Q Q2 2026, Consolidated Balance Sheets). Liquidity (cash plus revolver availability) stood at $1,000.8 million at year-end 2025 and $916.1 million at June 2026 (10-K 2025, MD&A; 10-Q Q2 2026, MD&A). The weighted-average interest rate on the term loan was reduced by 25 bps in March 2025 (10-K 2025, Note 4).

6. Data Gaps

• Standalone quarterly cash flow statements for Q1 2026 and Q2 2026 (only six-month YTD figures are provided in the 10-Q XBRL data).
• Q3 2025 and Q3 2024 results for a full quarterly year-over-year comparison (the 10-Q for 2025-09-30 was provided but its financial statement tables were truncated in the input).
• Segment-level cash flow and capital expenditure breakdowns for 2026 quarters.
• Detailed working capital component changes (receivables, inventory, payables) for 2026 quarters beyond the high-level commentary.
• Full-year 2026 results (only six months available).